John M.L. Ebos

5.5k citations

49 papers · 4.1k indexed · 2 hit papers · h-index 23

Impact in

Cancer Research top 1%
- Cancer, Hypoxia, and Metabolism
- Cancer Genomics and Diagnostics
Modeling and Simulation top 1%
- Mathematical Biology Tumor Growth

Papers in ⓘ

Cancer Research 20
- Cancer, Hypoxia, and Metabolism 8
- Cancer Genomics and Diagnostics 7
Oncology 25
- Cancer Cells and Metastasis 8
- Cancer Treatment and Pharmacology 7
- Cancer Immunotherapy and Biomarkers 6

Co-authors: Robert S. Kerbel (20 shared papers)Christina R. Lee (11 shared papers)James G. Christensen (4 shared papers)William Cruz‐Muñoz (2 shared papers)Georg A. Bjarnason (2 shared papers)Amanda Tracz (9 shared papers)Sébastien Benzekry (6 shared papers)Anthony J. Mutsaers (4 shared papers)
Journals: Cancer Research (6 papers)Clinical Cancer Research (3 papers)Molecular Cancer Therapeutics (3 papers)PLoS Computational Biology (3 papers)Cancers (2 papers)
Partner nations: United States Canada France

In The Last Decade

John M.L. Ebos

45 papers receiving 4.0k citations

Hit Papers

align trajectories log scale

Antiangiogenic therapy: impact on invasion, disease progression, and metastasis 2011 · 548 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2011 Nature Reviews Clinical Oncology
2009 Cancer Cell

Peers

Countries citing papers authored by John M.L. Ebos

Since Specialization

Citations

This map shows the geographic impact of John M.L. Ebos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John M.L. Ebos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John M.L. Ebos more than expected).

Fields of papers citing papers by John M.L. Ebos

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John M.L. Ebos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John M.L. Ebos. The network helps show where John M.L. Ebos may publish in the future.

Co-authors

The 25 scholars most cited alongside John M.L. Ebos, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with John M.L. Ebos Line = papers co-authored together John M.L. Ebos links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 49 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis Cancer Cell ·John M.L. Ebos, Christina R. Lee, William Cruz‐Muñoz, Georg A. Bjarnason, James G. Christensen, Robert S. Kerbel Hit paper breakdown →	2009	1383
2	Antiangiogenic therapy: impact on invasion, disease progression, and metastasis Nature Reviews Clinical Oncology ·John M.L. Ebos, Robert S. Kerbel Hit paper breakdown →	2011	548
3	Classical Mathematical Models for Description and Prediction of Experimental Tumor Growth PLoS Computational Biology ·Sébastien Benzekry, Clare Lamont, Afshin Beheshti, Amanda Tracz, John M.L. Ebos, Lynn Hlatky, Philip Hahnfeldt	2014	364
4	Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy Proceedings of the National Academy of Sciences ·John M.L. Ebos, Christina R. Lee, James G. Christensen, Anthony J. Mutsaers, Robert S. Kerbel	2007	295
5	Tumor and Host-Mediated Pathways of Resistance and Disease Progression in Response to Antiangiogenic Therapy Clinical Cancer Research ·John M.L. Ebos, Christina R. Lee, Robert S. Kerbel	2009	228
6	A Naturally Occurring Soluble Form of Vascular Endothelial Growth Factor Receptor 2 Detected in Mouse and Human Plasma Molecular Cancer Research ·John M.L. Ebos, Guido Bocci, Shan Man, Philip E. Thorpe, Daniel J. Hicklin, Danielle Zhou, Xiaohong Jia, Robert S. Kerbel	2004	159
7	Increased Plasma Vascular Endothelial Growth Factor (VEGF) as a Surrogate Marker for Optimal Therapeutic Dosing of VEGF Receptor-2 Monoclonal Antibodies Cancer Research ·Guido Bocci, Shan Man, Shane K. Green, Giulio Francia, John M.L. Ebos, Jeanne M. du Manoir, Adina Weinerman, Urban Emmenegger, Li Ma, Philip E. Thorpe, Andrew M. Davidoff, James Huber, Daniel J. Hicklin, Robert S. Kerbel	2004	128
8	Angiogenesis and the Tumor Microenvironment: Vascular Endothelial Growth Factor and Beyond Seminars in Oncology ·Kriti Mittal, John M.L. Ebos, Brian I. Rini	2014	116
9	Population modeling of tumor growth curves and the reduced Gompertz model improve prediction of the age of experimental tumors PLoS Computational Biology ·Cristina Vaghi, Anne Rodallec, Raphaëlle Fanciullino, Joseph Ciccolini, Jonathan P. Mochel, Michalis Mastri, Clair Poignard, John M.L. Ebos, Sébastien Benzekry	2020	98
10	Vascular Endothelial Growth Factor–Mediated Decrease in Plasma Soluble Vascular Endothelial Growth Factor Receptor-2 Levels as a Surrogate Biomarker for Tumor Growth Cancer Research ·John M.L. Ebos, Christina R. Lee, Elena Bogdanovic, Jennifer Alami, Paul Van Slyke, Giulio Francia, Ping Xu, Anthony J. Mutsaers, Daniel Dumont, Robert S. Kerbel	2008	95
11	Phase I/II Trial of Metronomic Chemotherapy With Daily Dalteparin and Cyclophosphamide, Twice-Weekly Methotrexate, and Daily Prednisone As Therapy for Metastatic Breast Cancer Using Vascular Endothelial Growth Factor and Soluble Vascular Endothelial Growth Factor Receptor Levels As Markers of Response Journal of Clinical Oncology ·Nan Soon Wong, Robert Buckman, Mark Clemons, Shailendra Verma, Susan Dent, Maureen Trudeau, Kathie Roche, John M.L. Ebos, Robert S. Kerbel, Gerrit DeBoer, D. J. Sutherland, Urban Emmenegger, Joyce M. Slingerland, Sandra Gardner, Kathleen I. Pritchard	2009	72
12	Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia. PubMed ·John M.L. Ebos, Jennifer M. Tran, Zubin Master, Daniel Dumont, Junia V. Melo, Elisabeth Buchdunger, Robert S. Kerbel	2002	64
13	Modeling Spontaneous Metastasis following Surgery: An In Vivo-In Silico Approach Cancer Research ·Sébastien Benzekry, Amanda Tracz, Michalis Mastri, Ryan Corbelli, Dominique Barbolosi, John M.L. Ebos	2015	48
14	Prodding the Beast: Assessing the Impact of Treatment-Induced Metastasis Cancer Research ·John M.L. Ebos	2015	47
15	A Novel 4-gene Score to Predict Survival, Distant Metastasis and Response to Neoadjuvant Therapy in Breast Cancer Cancers ·Masanori Oshi, Eriko Katsuta, Li Yan, John M.L. Ebos, Omar M. Rashid, Ryusei Matsuyama, Itaru Endo, Kazuaki Takabe	2020	46
16	Cellular and Molecular Surrogate Markers to Monitor Targeted and Non- Targeted Antiangiogenic Drug Activity and Determine Optimal Biologic Dose Current Cancer Drug Targets ·Yuval Shaked, Guido Bocci, Raquel Muñoz, Shan Man, John M.L. Ebos, Daniel J. Hicklin, Francesco Bertolini, Robert J. D’Amato, Robert S. Kerbel	2005	35
17	Down-regulation of DNA mismatch repair proteins in human and murine tumor spheroids: implications for multicellular resistance to alkylating agents Molecular Cancer Therapeutics ·Giulio Francia, Shane K. Green, Guido Bocci, Shan Man, Urban Emmenegger, John M.L. Ebos, Adina Weinerman, Yuval Shaked, Robert S. Kerbel	2005	34
18	Neoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy EMBO Molecular Medicine ·John M.L. Ebos, Michalis Mastri, Christina R. Lee, Amanda Tracz, John M. Hudson, Kristopher Attwood, William Cruz‐Muñoz, Christopher Jedeszko, Peter N. Burns, Robert S. Kerbel	2014	33
19	Dose-Dependent Increases in Circulating TGF-α and Other EGFR Ligands Act As Pharmacodynamic Markers for Optimal Biological Dosing of Cetuximab and Are Tumor Independent Clinical Cancer Research ·Anthony J. Mutsaers, Giulio Francia, Shan Man, Christina R. Lee, John M.L. Ebos, Yan Wu, Larry Witte, Scott Berry, Malcolm J. Moore, Robert S. Kerbel	2009	33
20	Preclinical recapitulation of antiangiogenic drug clinical efficacies using models of early or late stage breast cancer metastatis The Breast ·Robert S. Kerbel, Éric Guérin, Giulio Francia, Ping Xu, Christina R. Lee, John M.L. Ebos, Shan Man	2013	30

About John M.L. Ebos

John M.L. Ebos is a scholar working on Cancer Research, Oncology, Biotechnology, Modeling and Simulation and Pulmonary and Respiratory Medicine, having authored 49 papers that have together received 4.1k indexed citations. Recurring topics across this work include Angiogenesis and VEGF in Cancer (18 papers), Renal cell carcinoma treatment (9 papers), Cancer Cells and Metastasis (8 papers), Cancer, Hypoxia, and Metabolism (8 papers), Cancer Treatment and Pharmacology (7 papers), Cancer Research and Treatments (7 papers), Cancer Genomics and Diagnostics (7 papers) and Cancer Immunotherapy and Biomarkers (6 papers). The work is most often cited by research in Cancer Research (1.5k citations), Modeling and Simulation (341 citations), Oncology (1.6k citations), Hepatology (281 citations) and Molecular Biology (2.3k citations). John M.L. Ebos has collaborated with scholars based in United States, Canada and France. Frequent co-authors include Robert S. Kerbel, Christina R. Lee, James G. Christensen, William Cruz‐Muñoz, Georg A. Bjarnason, Amanda Tracz, Sébastien Benzekry, Anthony J. Mutsaers, Philip Hahnfeldt and Afshin Beheshti. Their work appears in journals such as Cancer Research, Clinical Cancer Research, Molecular Cancer Therapeutics, PLoS Computational Biology and Cancers.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact